Abstract: The present disclosure relates to heteroaryl derivatives and their uses thereof. The heteroaryl derivatives of the present disclosure exhibit excellent inhibitory activity against PKMYT1 and/or CCNE1, can be useful as therapeutic agents for diseases related to the overactivation, amplification, or overexpression of PKMYT1 and/or CCNE1.

Abstract: The present invention relates to an aryl or heteroaryl derivative and a pharmaceutical composition for the treatment of kinase-related diseases comprising same as an active ingredient. An aryl or heteroaryl derivative provided according to an aspect of the present invention exhibits excellent inhibitory activity against kinases, especially receptor-interacting serine/threonine-protein kinase 1 (RIPK1), and thus can be used as a therapeutic agent for RIPK1-related diseases.

Abstract: Provided are transgenic organisms, such as plants and plant parts, cells, and related compositions and methods for producing and monitoring the genotype for enhanced production of montbretin A and/or its precursors. For example, provided is a transgenic organism comprising at least one heterologous nucleic acid operatively linked to a promoter, wherein the heterologous nucleic acid encodes at least one enzyme in a montbretin A (MbA) metabolic pathway. The organisms can be a plant, plant part, or plant cell, or a microorganism such as a yeast. Also provided is a method for producing at least one montbretin A (MbA) precursor and/or MbA, comprising permitting the expression of the at least one heterologous nucleic acid in the transgenic organism. The disclosure also provides isolated nucleic acid molecules that comprise sequence encoding at least one enzyme in a montbretin A (MbA) metabolic pathway and vectors comprising the nucleic acids.

Abstract: The N-(3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylphenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide derivative exhibits excellent inhibitory activity against at least one kinase selected from the group consisting of ABL1, ABL2, AURKB, BRK, CDK11, CDK8, CDK9, CDKL2, CIT, DDR1, FLT3, HIPK4, HUNK, JAK3, KIT, LOK, LTK, MET, MLK2, MUSK, MYO3A, PAK3, PCTK3, PDGFRA, PDGFRB, RIPK1, TIE1 and ZAK, and thus being useable as a therapeutic agent for kinase-related disease.